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ABSTRACT
Hepatocyte-like cells (HLCs) differentiated from human induced
pluripotent stem cells (iPSCs) offer an alternative model to primary
human hepatocytes to study lipid aberrations. However, the detailed
lipid profile of HLCs is yet unknown. In the current study, functional
HLCs were differentiated from iPSCs generated from dermal
fibroblasts of three individuals by a three-step protocol through the
definitive endoderm (DE) stage. In parallel, detailed lipidomic
analyses as well as gene expression profiling of a set of lipid-
metabolism-related genes were performed during the entire
differentiation process from iPSCs to HLCs. Additionally, fatty acid
(FA) composition of the cell culture media at different stages was
determined. Our results show that major alterations in the molecular
species of lipids occurring during DE and early hepatic differentiation
stages mainly mirror the quality and quantity of the FAs supplied in
culture medium at each stage. Polyunsaturated phospholipids and
sphingolipids with a very long FAwere produced in the cells at a later
stage of differentiation. This work uncovers the previously unknown
lipid composition of iPSC-HLCs and its alterations during the
differentiation in conjunction with the expression of key lipid-
associated genes. Together with biochemical, functional and gene
expression measurements, the lipidomic analyses allowed us to
improve our understanding of the concerted influence of the
exogenous metabolite supply and cellular biosynthesis essential for
iPSC-HLC differentiation and function. Importantly, the study
describes in detail a cell model that can be applied in exploring, for
example, the lipid metabolism involved in the development of fatty
liver disease or atherosclerosis.
KEY WORDS: Induced pluripotent stem cell, iPSC, Hepatocyte-like
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INTRODUCTION
The liver is the main metabolic and synthetic organ in the human
body, carrying out more than 500 different functions. It is mainly
composed of hepatocytes, which constitute approximately 60% of
the cells in the liver and possess many important functions.
Hepatocytes produce the majority of circulating plasma proteins,
including transporters (such as albumin and lipoproteins), protease
inhibitors (α1-antitrypsin, antithrombin and α2-macroglobulin),
blood coagulation factors, and modulators of immune complexes
and inflammation (complement C3, C-reactive protein).
Hepatocytes also control the homeostasis of energy/fuel
molecules such as glucose/glycogen and fatty acids (FAs) as well
as other essential compounds of lipid metabolism such as
cholesterol and bile acids. Additionally, liver has a central role in
lipid metabolism as it is the major site for the generation of plasma
lipoproteins (Godoy et al., 2013).
The use of hepatocytes as in vitro models to explore different
aspects of liver function and metabolism has escalated in recent
years but primary human hepatocytes (PHHs), the key in vitro cell
type involved in e.g. cholesterol metabolism, are scarce because
they are obtained from organ donors. Furthermore, when in culture
the PHHs quickly dedifferentiate and lose their liver functions, thus
making them impractical for modelling the liver in vivo (Elaut et al.,
2006). Human induced pluripotent stem cell (iPSC)-derived
hepatocytes provide a good alternative to PHHs because iPSCs
can be easily reprogrammed from dermal fibroblasts and then
differentiated into hepatocyte-like cells (HLCs), which functionally
resemble PHHs (Hu and Li, 2015). iPSC-HLCs can recapitulate
metabolic variations observed in the population and have proved to
be potent in both short- and long-term drug screening and in
investigating hepatotoxicity or developing novel therapeutics
(Holmgren et al., 2014; Medine et al., 2013; Szkolnicka et al.,
2014). In addition, they have been utilised for studying fetal liver
exposure to harmful substances (Lucendo-Villarin et al., 2017) and
in identifying noncoding micro-RNAs regulating human liver
damage (Szkolnicka et al., 2016; Yang et al., 2016). Furthermore,
HLCs have been successfully used in developing in vitromodels for
studying hepatic diseases such as systemic amyloidosis (Leung
et al., 2013), liver-stage malaria (Ng et al., 2015) and hepatitis C
viral infection (Zhou et al., 2014). iPSC-HLCs could also offer a
good model for investigating basic mechanisms of e.g. lipid
metabolism as well as its dysregulation related to different diseases
such as fatty liver disease or atherosclerosis.
Lipids are a highly diverse class of biological molecules with
crucial roles in cellular energy storage (mainly in the form of
triacylglycerols), structure (e.g. key components of plasma and
nuclear membranes, endoplasmic reticulum and Golgi apparatus,
and trafficking vesicles like endosomes and lysosomes) and
signalling (as ligands that activate signal transduction pathways as
well as mediators of signalling pathways) (Van Meer et al., 2008).
Furthermore, de novo FA synthesis in the cells has a significant
impact on the acquisition and maintenance of cellular pluripotency
through increased mitochondrial fission (Wang et al., 2017).
Mammalian cells express tens of thousands of different lipid
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transport them (Muro et al., 2014). Moreover, lipid defects are
central to the pathogenesis of many common diseases such as non-
alcoholic fatty liver disease (Ruhanen et al., 2017; Younossi et al.,
2016) or atherosclerosis (Meikle et al., 2011; Stübiger et al., 2012).
However, because the cellular lipidome is highly complex and very
dynamic, the study of lipids and identifying the precise underlying
defects has previously been hampered by analytical limitations.
This has been resolved by the emergence of advanced lipidomic
technologies. Lipidomics aims to precisely define and quantitate the
molecular profiles of lipids present in a cell, organism or tissue
(Watson, 2006; Wenk, 2005), and provides precise quantitative
snapshots of the lipidomes comprising hundreds of different
molecules (Llorente et al., 2013; Sales et al., 2016). This
technological advancement in conjunction with computational
technologies has made this field a promising area for biomedical
research (Ekroos, 2012).
In this study, we produced iPSCs from patient-derived dermal
fibroblasts and differentiated them into HLCs. In total, we
quantified 165 molecular species of lipids, and are the first to
report a comprehensive lipidomic profile of cells during the entire
differentiation process from iPSCs through the definitive endoderm
(DE) stage to HLCs. We assess the occurring lipidomic alterations
in relation to the variable supply of different FAs measured in the
cell culture media at each stage of the differentiation. Thus, we do
not overlook the comprehensive effects of the essential exogenous
metabolites the cells acquire from the culture medium. Additionally,
we present biochemical and functional measurements and
expression of sphingolipid (SL) metabolism-related genes during
HLC differentiation.
RESULTS
Characterisation of the iPSC lines
The three iPSC lines used in this study – UTA.10100.EURCAs,
UTA.11104.EURCAs and UTA.11304.EURCCs –were characterised
in detail for their pluripotency. All three iPSC lines expressed
characteristic markers of pluripotency at the protein (Fig. S1A) and
gene (Fig. S1B) level, and the virally transferred exogenous
pluripotency genes were silenced (Fig. S1C). The pluripotency of
iPSC lines was proven in vitro by embryoid body (EB) formation
and performing PCR to show the presence of all three germ layers
(Fig. S1D). The karyotypes of all three iPSC lines were normal
(Fig. S2).
Differentiation of iPSCs to HLCs through a DE stage
We used a previously described three-step protocol (Hay et al.,
2008) to produce HLCs from human iPSCs (Fig. 1A). During the
differentiation process, the cells underwent morphological changes:
iPSCs gradually lost their typical round and dense morphology and
after migration formed spiky-shaped DE cells. During the second
week of differentiation, at the hepatoblast stage, cells gradually
increased in size and, as they matured during the third week, formed
polygonal HLCs with distinct canaliculated borders (Fig. 1B). The
immunocytochemical staining at day 5 showed that cells expressed
only low levels of pluripotency marker OCT3/4 but were strongly
positive for the DE marker SOX17 (Fig. S3A). Furthermore, flow
cytometry analyses showed that 71-96% of the cells were positive
for the DE marker CXCR4 at day 5 of differentiation (Fig. S3B).
These results indicated that the iPSCs had efficiently differentiated
into DE during the endodermal induction step of the differentiation
protocol.
Consistent with the morphological changes observed during the
differentiation process (Fig. 1B), changes in gene expression were
detected (Fig. S3C). The expression of OCT3/4 was clearly
downregulated by day 5, whereas the DE marker SOX17 was
highly expressed at this stage. FOXA2, a transcription factor
involved in liver metabolism (Wolfrum et al., 2004), had a
continuous expression pattern starting around day 5 and
continuing until the end of differentiation. As the cells
differentiated further from DE towards HLCs, they started
expressing AFP (around day 10, which peaked around day 15-20
depending on the cell line). Expression of ALB, the gene for the
most abundant liver protein, increased strongly around day 15 and
peaked at day 20-25 (Fig. S3C). Immunocytochemical staining
further confirmed the expression of hepatic proteins at day 20 of
differentiation (Fig. 1C,D). Low-density lipoprotein receptor
(LDL-R), asialoglycoprotein receptor (ASGR), alpha fetoprotein
(AFP) as well as albumin (ALB) were all expressed in HLCs
(Fig. 1C,D). HLCs stained positive for ALB in 13, 18 and 19% of
the cells differentiated from UTA.10100, UTA.11104 and
UTA.11304, respectively. Both AFP and ASGR stained positive
in more than 90% of HLCs in all three cell lines.
Functionality assessment of mature HLCs
To assess the functionality of the iPSC-HLCs, we performed several
experiments. Because liver is the most important organ for LDL
catabolism and LDL-R activity, the ability of HLCs to uptake LDL
from the culture mediumwas evaluated. As shown in Fig. 1E, iPSC-
HLCs were able to efficiently uptake LDL. The level of secreted
albumin was measured from the cell culture medium at days 14, 17,
20 and 23 of differentiation, and all the iPSC-HLCs synthesised and
released albumin into the culture medium with maximum secretion
at day 20 (Fig. 1F).
Apolipoprotein B (APOB) and apolipoprotein A-I (APOA1) gene
expression levels of the iPSC-HLCs during the differentiation were
also measured as a surrogate for estimating very low-density
lipoprotein (VLDL) and high-density lipoprotein (HDL) production
levels of the cells. APOB is the main protein component of VLDL,
and the product of the APOA1 gene is the main protein component
of HDLs. The expressions of both APOB and APOA1 genes rose
around day 10, reached their peak at day 15 and then lowered
towards the levels of expression in PHHs (Fig. 1G,H). The
increasing expression of these liver-specific genes further
demonstrated that the iPSCs were differentiating and maturing
towards functional hepatocytes.
Lipidomic profiling of iPSC-HLCs
We performed lipidomic profiling of the cells during the entire
differentiation process from iPSCs to HLCs, and observed changes
in cellular lipid content and composition. Overall, more than 160
molecular species of lipids including cholesteryl esters (CEs),
diacylglycerols (DAGs), phospholipids (PLs) and SLs were
detected during the course of differentiation (Table S5). The
cellular contents of lipid classes (per protein) were constantly
altered during the differentiation. In the beginning, the protein-
normalised concentrations of the majority of lipid classes decreased
from day 0 to day 6, which mostly mirrors the low supply of lipids or
FAs from the culture media at this stage (Fig. 2A,B). However, clear
increases were observed in three classes – sphingomyelin (SM), CE
and phosphatidylinositol (PI) – independent of the lower or
undetectable levels of those lipids in medium B. This was
followed by a drastic increase in all lipid classes from day 6 to
day 12, which clearly reflected the abundant lipid and FA in
medium C (supplied to the cells from ∼day 7 to day 12). Thus, the
amount of FAs and lipids available in the media affects the lipid
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composition and content of the cells. The measured concentrations
of medium lipids and FAs were nicely in line with each other
(Fig. 2A,B). During the hepatic maturation, from ∼day 12 onwards,
changes in the lipid levels were more subtle, in agreement with the
constant FA level of medium D, which was given to the cells during
the hepatic maturation phase and contained on average 32.0 nmol
FA/ml of medium (Fig. 2A). Principal component analysis (PCA)
showed that the cellular lipid composition of iPSCs and DE stage
Fig. 1. See next page for legend.
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cells (days 0 and 6, respectively) clearly differs from the later time
points representing hepatoblasts (day 12) and HLCs (day 16-28)
(Fig. 2C). A similar PCA plot pattern was detected for the FA
composition of cell culture media (Fig. 2D).
To visualise the alterations occurring in the cellular lipidome
during the iPSC to HLCs differentiation in more detail, a heat map
was computed using day 0 as the reference and including all the
detected molecular lipids (Fig. S4A). Because the biggest alterations
in the cellular lipid content and composition happened before day 12
as observed in the PCA (Fig. 2C) and appeared mostly to reflect the
FA supply from the media, we computed another heat map using day
12 as the reference (Fig. S4B). From this heat map, the lipid
remodelling during the hepatocyte maturation phase became more
evident as the fluctuation from days 0 to 6 was excluded. We further
restricted the heat map to include only molecular lipids, the
concentration of which changed statistically significantly between
days 12 and 28 (P<0.05). In the resulting heat map, 41 molecular
lipids divided into two distinct clusters visible on the heat map
dendrogram (Fig. 2E). The upper cluster consists of mainly SLs with
very-long-chain FAs (C24-26), levels of which increased during the
maturation. Lipids that decreased after day 12 are clustered in the
lower part of the heat map consisting of several CE species as well as
lipids containing FA 18:2 [linoleic acid (LA)]. Similar phenomena
were observed in another heat map drawn separately for the 45 FAs
present in specific lipid classes in the cells (Fig. S5).
We detected 16 different CE species, the most abundant during
the iPSC to HLC differentiation being CE 18:1, CE 16:0 and CE
18:0 (Fig. 3A, lines), concurring with the higher level of FAs 16:0,
18:0 and 18:1 available in the medium C (Fig. 3A, columns).
Interestingly, CE 18:0 concentration was low in medium C whereas
CE 18:2 was detected the highest (Fig. 3A, insert). This CE 18:2
loading did not cause comparable accumulation of CE 18:2 in the
cells. The majority of CEs peaked at day 12, with the exception of
CE 20:1 (peak day 16) and CE 20:3, CE 22:5 and CE22:6 (peak day
24). The decrease of several CEs and the increase of CE 22:6 are
clearly visible in the heat maps, illustrating the statistically
significant lipid and FA changes between days 12 and 28
(Fig. 2E, Fig. S5). It is of note that only the last medium (medium
D, given to the cells from ∼day 13 onwards) provided the cells
abundantly with FA 22:6 (Fig. 3A).
During hepatic differentiation and maturation, we detected an
overall increase in the FA chain length of SLs (Fig. 3B). The C16-18
species predominated (64%) in the beginning of differentiation but
their relative abundance gradually decreased (to 44%) during the
hepatocyte maturation process. At day 6, a temporary increase in
the proportion of the C16-18 species was detected. Interestingly, as
the differentiation progressed, the SL chain length profile
approached that of PHHs, in which the very-long-chain species
(C20-26) predominate (Fig. 3B).
Closer examination of the PL molecular species revealed that the
largest changes occurred in polyunsaturated fatty acid (PUFA)-
containing lipid species, whereas lipids comprised of saturated or
monounsaturated FAs (SFA or MUFA, respectively) were more
constant throughout the entire differentiation (Fig. 3C, Table S5). The
polyunsaturated lipid species were essentially absent at the beginning
of differentiation and increased drastically until day 12 or 16, reflecting
the increasing concentrationofn-3 and n-6 PUFAs in themedia during
differentiation, as shown in Fig. 3C for the phosphatidylcholines
(PCs). On the other hand, the PCs containing FA 22:5 and 22:6
appeared later during the differentiation and at a lower concentration,
consistentwith their lowmediumconcentration aswell as a late and (as
compared to n-6 PUFAs) low level supply of n-3 PUFAs from the
medium (Fig. 3C). Lipids with different PUFA constituents mostly
peaked around day 12, after which they steadily decreased following
the pattern of medium FA 18:2 and 18:3 levels, which were at the
highest inmediumC (during∼days 7-13) and then dropped to a lower
level for the rest of the differentiation (Fig. 4). The molecular species
containing FA 20:3 and FA 20:4 peaked around day 12, reflecting the
media rich in their C18 precursors, and then their contents remained at
the fairly constant level due to the later moderate supply of FA 20:3
and 20:4 themselves (Fig. 4). The n-3 PUFA precursor, FA 18:3, and
the successors on the metabolic pathway, FA 20:5 and 22:5, were not
able to efficiently raise the levels of the 22:6-containing species,
which peaked only during days 16-24, i.e. after switching to 22:6-rich
medium (Fig. 4, lower row).
Gene–lipid interaction
Levels of several ceramides with very-long-chain FAs, e.g. Cer
d18:1/26:1 and Cer 18:1/26:0, increased statistically significantly
during the hepatic maturation phase (Fig. 2E). Ceramide synthesis
involves six different ceramide synthases (CerSs): CerS1-CerS6.
The CERS1 gene was the only highly expressed ceramidase gene at
the iPSC stage and it gradually reduced to the expression levels
detected in PHHs (Fig. 5A). The expression of the CERS2 gene, by
contrast, slowly increased during hepatocyte differentiation,
reaching the expression level in PHHs by day 20 of differentiation
(Fig. 5A). A statistically significant correlation was observed
between CERS2 expression and the very-long-chain ceramides Cer
d18:1/24:0 (r=0.83, P<0.0001), Cer d18:1/23:0 (r=0.78, P<0.001)
and Cer d18:1/26:0 (r=0.73, P<0.001) (Fig. 5B). A similar gene
expression pattern to CERS2 was observed for CERS3. CERS4
expression varied whereas that ofCERS6 gradually increased during
the differentiation, and CERS5 was ubiquitously expressed
throughout the differentiation (Fig. S6A).
Ceramides are degraded to sphingosine and free FAs by
ceramidases encoded by distinct genes such as ASAH1 and ASAH2.
The expression of ASAH1 increased during the differentiation (Fig.
S6B). ASAH2 expression peaked strongly at day 15 and then
gradually reduced towards the levels detected in PHHs. ASAH2b
expression was constant throughout the differentiation and at the
same level as in PHHs, only peaking slightly at day 15 (Fig. S6B).
Lactosylceramide (LacCer) and glucosyl/galactosylceramide
(Glc/GalCer) are members of the glycosphingolipid (GSL) family
and the UDP-glucose:ceramide glucosyltransferase (UGCG) gene
Fig. 1. Hepatic differentiation of iPSCs through the definitive endoderm
(DE) stage. (A) A schematic representation of the hepatic differentiation
protocol (modified from Hay et al., 2008) and cell culture media used at each
stage. See text for details of the media. (B) Phase-contrast images showing
sequential morphological changes from iPSCs (day 0) to DE (day 5) and finally
hepatocyte-like cells (HLCs) (day 20) during differentiation. (C,D)
Immunocytochemistry of the iPSC-HLCs differentiated from three patient lines
(UTA.10100.EURCAs, UTA.11104.EURCAs andUTA.11304.EURCCs) at day
20 showing the expression of (C) LDL receptor (LDL-R) and asialoglycoprotein
receptor (ASGR), as well as (D) α-fetoprotein (AFP) and albumin (ALB). Nuclei
are stained with DAPI. (E) The iPSC-HLCs were able to uptake LDL at day 20
of differentiation and (F) produce and secrete albumin during differentiation.
Values are normalised per 1 million cells per 24 h. Bars represent means±s.d.
of three biological replicates. Gene expression levels of (G) apolipoprotein B
(ApoB) and (H) apolipoprotein AI (ApoAI) at different time points during the
iPSC to HLC differentiation normalised to the housekeeping gene GAPDH,
and expressed relative to day 0. Each sample was run in triplicate and bars
represent means±s.d. of three studied cell lines. iPSC, induced pluripotent
stem cell; KO-DMEM, KnockOut Dulbecco’s modified Eagle medium; DMSO,
dimethyl sulfoxide; HGF, hepatocyte growth factor; OSM, oncostatin M; PHH,
primary human hepatocyte. Scale bars: 200 μm.
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encodes the enzyme that catalyses the first glycosylation step in
GSL biosynthesis. There was a statistically significant increase in
four different GSLs, including LacCer d18:1/26:0 and Glc/GalCer
d18:1/26:1, during the hepatic maturation phase (Fig. 2E).
Compatibly, UGCG expression increased during the iPSC-HLC
differentiation (Fig. 5A), and we observed a statistically significant
correlation between UGCG expression and the total level of Glc/
GalCer (r=0.54, P<0.05), particularly with Glc/GalCer d18:1/26:0
(r=0.84, P<0.0001) (Fig. S6C).
An almost fourfold increase in total SM level was detected from
day 0 to day 28 of the iPSC-HLC differentiation (Fig. 2A).
Specifically, an increase in the longer (C23-26) SM species was
observed (Fig. S7A). SM is metabolised from ceramides by SM
synthases (SMS1 and SMS2). The expression of the corresponding
Fig. 2. Changes in the lipidome during iPSC to hepatocyte-like cell (HLC) differentiation. (A) Lines describe the total concentration of different lipid classes
detected in the cells at seven timepoints during the iPSC toHLCdifferentiation.Bars represent the total FA concentration (nmol FA/ml ofmedium) of differentmedia
used during hepatic differentiation. Values at the top of bars and the top line show the total concentrations of FAs in the medium and PC in the cells, respectively.
(B) Total concentration (µM) of different lipid classes in culture medium A, B, C and D. (C) Principal component analysis (PCA) plot showing the separation of
samples based on lipid profiles. PCA analysis of the 165molecular lipids showed that the two first principal components constitute 63.2% of the variance. (D) PCA
analysis of the FA content of cell culture media used at different stages of hepatic differentiation. (E) Lipidomic heat map showing fold increase of molecular lipid
species at day 16, 20, 24 and 28 of iPSC to HLC differentiation as compared to day 12. Each horizontal row represents a molecular lipid and each vertical column
represents an individual time point of the differentiation. Lipid abundance ratios are coloured according to the fold changes and the colour key indicates the
magnitude of log2 fold change. Data shown are the lipids for which concentration differed statistically significantly (P<0.05) between day 12 and day 28. iPSC,
induced pluripotent stem cell; CE, cholesteryl ester; Cer, ceramide; DAG, diacylglycerol; Gb3, globotriaosylceramide; Glc/GalCer, glucosyl/galactosylceramide;
LacCer, lactosylceramide; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanoamine; PC, phosphatidylcholine; PCO, alkyl-linked phosphatidylcholine;
PE, phosphatidylethanolamine; PE O, alkyl-linked phosphatidylethanolamine; PI, phosphatidylinositol; PS, glycerophosphoserine; SM, sphingomyelin.
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genes, SGMS1 and SGMS2, increased during differentiation, reaching
the expression levels of PHHs by day 10 (Fig. 5A). A statistically
significant correlation was detected between SGMS2 expression and
levels of very-long-chain SMs (Fig. 5C) such as d18:1/24:0 (r=0.82,
P<0.0001), SM d18:1/24:1 (r=0.78, P<0.001) and SM d18:1/26:1
(r=0.67, P<0.01). Levels of these very-long-chain SMs increased
independently of the exogenous lipid supplies during the hepatoblast
phase, whereas the shorter-chain SMs such as SMd18:1/18:0 and SM
d18:1/18:1 decreased at the hepatic maturation stage (Fig. S7A,B).
Several different sphingomyelinase (Smase) enzymes degrade SMs.
The SMPD1 gene encodes a lysosomal acid Smase, the expression of
which increased during the hepatic differentiation (Fig. 5A) along
with the expression of another sphingomyelinase gene, SMPD3
(Fig. S7C). The expression of two other Smase genes, SMPD2 and
SMPD4, was fairly constant through the differentiation and similar to
that in PHHs (Fig. S7C).
DISCUSSION
In this study, we successfully produced functional HLCs from iPSCs
and describe a comprehensive lipidomic fingerprint of these cells in
conjunction with biochemical and functional measurements. We
quantitatively monitored a total of 165 molecular species of lipids
during the course of hepatic differentiation, as well as measuring the
concentrations of different lipids and FAs in the cell culture media at
each stage of differentiation. The analyses of lipids and FAs in the
media were complementary in characterising the supplies of the
cells. After commitment of the cells to the hepatic lineage (around
day 12), protein-normalised concentrations of most studied lipid
classes increased. These included functionally important specific
PLs and SLs but, as expected, the main building blocks of bulk
membrane, PC and PE, showed less variation. At the same time, the
levels of storage lipids were elevated, indicated by the increased CE
totals. DAGs were also analysed because they are an important
intermediary lipid class between the storage and structural lipids,
and their elevated levels at day 12 indicate enhanced lipid
metabolism (complex triacylglycerol molecular species were not
addressed in this study). These lipidome alterations mirror the large
increase in medium FA levels and improved supply of PUFAs to the
cells. Simultaneously, the cells grew in size and approached
hepatocyte cell morphology. Along with the influence of
Fig. 3. Changes in cholesteryl ester (CE),
polyunsaturated fatty acid (PUFA)-containing
phosphatidylcholine (PC) species and the chain length
of sphingolipids (SLs) during the iPSC to hepatocyte-
like cell (HLC) differentiation. (A) Lines represent the
concentration (pmol/µg total protein) of all detected CE
species at different time points of the iPSC to HLC
differentiation. Concentrations are presented on a
logarithmic scale. Bars represent concentration of all
different FAs (nmol FA/ml of medium) detected in different
cell culture media used during hepatic differentiation. The
insert on the lower right shows the concentration (µM) of CE
species detected in culture medium A, B, C and D. No CE
species were detected in medium B. (B) The distribution of
SLs with different FA chain lengths at different time points
shows that, during hepatic differentiation and maturation,
the relative abundance of C16-18 species gradually
decrease, whereas C23-24 species increase. At the end of
the hepatic maturation phase, the distribution closely
resembles that of primary human hepatocytes (Hu8209 and
Hu8210). All SLs detected were included in the
calculations. (C) Lines represent the concentrations (pmol/
µg total protein) of selected PC species at different time
points. The levels of saturated/monounsaturated FA (in
blue)-containing species remain rather constant, whereas
levels of PUFA-containing lipid species (20:4 in red; 22:5/
22:6 in orange) emerge/increase considerably at day 6 and
12. Bars represent the total n-3 FA, n-6 FA and FA 22:6
concentration (nmol FA/ml of medium) in cell culture media
at each stage of differentiation. The insert on the lower right
shows the concentration (µM) of PC species detected in
culture mediumA, B, C andD. PCs 18:0/22:5 and 18:0/22:6
were not detected in the media. Values at the top line show
the concentration of PC 16:0/18:1 in the cells during
differentiation.
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exogenous supplies, we also found endogenous cellular responses:
specific SL-metabolism-related genes correlated with distinct SL
species levels, which showed that, during the differentiation,
changes in gene expression levels were reflected in the levels of
specific lipid species at a given time point.
Cholesterol biosynthesis is one of the important functions of
hepatic cells. Interestingly, the three most abundant storage forms of
CEs detected during the differentiation of iPSCs to HLCs, i.e. CE
18:1, CE 16:0 and CE 18:0, have previously been shown to be
among the most abundant CEs in the human liver (Nestel and
Couzens, 1966). Despite the level of CE 18:2 being very high in
media C and D, when analysing cellular CE levels, this species was
not among the highest species but the essential 18:2n-6 [linoleic
acid (LA)] was apparently incorporated into structural PLs, priming
these PUFAs for signalling. This gives confidence that lipid
metabolism of this cell model resembles that of genuine
hepatocytes. Most CE species were at their highest levels at day
12 and then, along with decreasing medium CE and FA levels, CEs
in the cells decreased during hepatocyte maturation. Compared to
medium A and B, medium C (provided to the cells from ∼day 7 to
∼day 13) contained a very high total concentration of FAs,
exceeding the sufficient amount for a cell’s consumption. This is
also consistent with our observation of lipid droplet (LD) formation
during the second week of differentiation (results not shown),
suggesting that the excess amount of FAs provided in medium C are
stored as LDs in the cells. LDs are the main reservoir for neutral
lipids in the cells and can be used for metabolism, membrane
synthesis (PLs and cholesterol) and steroid synthesis (Martin and
Parton, 2006).
SLs form a class of lipids defined by their C18 amino-alcohol
backbones, which are synthesised in the ER from non-SL
precursors. Modification of this basic structure gives rise to the
vast family of SLs such as ceramides, SMs and GSLs, which are
structural components of biological membranes and bioactive
molecules participating in diverse cellular activities such as cell
division, differentiation, gene expression and apoptosis (Gault et al.,
2010). SLs also participate in cell signalling and modulate
inflammation (Hannun and Obeid, 2008; Maceyka and Spiegel,
2014). Furthermore, increasing evidence shows that SLs contribute
to the pathogenesis of metabolic diseases including atherosclerosis
(Borodzicz et al., 2015; Haus et al., 2009; Hornemann and Worgall,
2013) and that SL metabolism is affected by dyslipidemia (Holland
and Summers, 2008). Because the liver is heavily involved in lipid
metabolism, hepatocytes offer a good cell model for studying the
basic mechanisms of lipid metabolism and its dysregulation.
The precursor of all SLs is ceramide, which primarily consists of
a sphingoid long-chain base (sphingosine) and one FA chain, the
length of which typically ranges from C14 to C26, the ceramide
species with FAs 16:0, 24:0 and 24:1 being predominant in most
mammalian tissues. Ceramide synthesis is a complex process and
orchestrated by six mammalian CerSs, each of which produces
ceramides with distinct FA chain lengths (Cingolani et al., 2016;
Levy and Futerman, 2010; Park et al., 2014). The expression pattern
of CerS is cell specific, which is reflected in the different SL acyl
chain composition in a given tissue (Levy and Futerman, 2010).
CerS2, the dominant CerS isoform found in the liver, utilises C20-
C26 acyl-CoA species as substrate and is one of the major CerSs
responsible for the synthesis of long-chain ceramide species
Fig. 4. The levels of polyunsaturated fatty acid (PUFA)-containing lipids during iPSC to HLC differentiation. Lines in the graphs show concentrations
(pmol/µg total protein; logarithmic scale on the left) of lipids containing the given PUFA moiety at different time points. Each line represents the lipid species with
the specific PUFA in a particular lipid class; line colour refers to lipid class (colour key depicted on the right). The bars represent the concentration of FA 18:2, 20:3,
20:4, 18:3, 20.5, 22:5 and 22:6 (nmol FA/ml of medium, scale on the right) in the cell culture media during hepatic differentiation. CE, cholesteryl ester; PC,
phosphatidylcholine; PC O/PC P, ether-linked PC; PE, phosphatidylethanolamine; PE O/PE P, ether-linked PE; PS, phosphatidylserine; FA, fatty acid.
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(C20-C26) (Laviad et al., 2008). In our study, the concentration of
several very-long-chain (C22 to C26) SLs increased statistically
significantly between days 12 and 28, which indicates an increase in
CerS2 activity as the cells matured towards functional HLCs. This
was supported by a clear and statistically significant increase
of CERS2 gene expression during iPSC-HLC differentiation.
Furthermore, a statistically significant positive correlation between
CERS2 expression and very-long-chain ceramides (e.g. Cer d18:1/
24:0) was found. The very-long-chain ceramides produced by
CERS2 are essential for liver function (Park et al., 2014); thus, the
increase in their levels acts as evidence of hepatocyte functionality.
Admittedly, we have not measured CERS2 enzyme activities but
only the level of CERS2 gene expression. Still, both the increased
CERS2 gene expression as well as the increase in long-chain
ceramides and other long-chain SLs showed that the stepwise
hepatic differentiation protocol produced iPSC-HLCs with a lipid
phenotype resembling that of PHHs. Ceramide can be degraded to
sphingosine and free FA by ceramidases (Mao and Obeid, 2008).
Acid ceramidase (encoded by the ASAH1 gene) most efficiently
hydrolyses ceramide with medium-chain FA components (C12 to
C14), whereas the neutral ceramidase (ASAH2) prefers long-chain
to very-long-chain components (C16 to >C24) (Gault et al., 2010).
In the current study, expression of ASAH1 and ASAH2b was rather
constant, whereas, concurrent with the increase in very-long-chain
ceramide, the expression of ASAH2 peaked at day 15 and then
gradually decreased towards levels in PHHs. These findings suggest
that there is a balance between ceramide production by CerS and
degradation by ceramidases during differentiation, which could
partly explain why ceramide levels stay constant towards the end
of the differentiation. The C26 FAs were not detected in any of the
culture media and the C26 species of ceramides and SLs
(synthesised from their precursor) were still found in the cells,
with increasing amounts towards the end of the differentiation
process. Thus, the levels and molecular species composition of
ceramide and the successor SLs seemed to be endogenously
regulated.
Total SM levels increased during iPSC-HLC differentiation. We
showed that the corresponding genes for SM synthases – SGMS1 and
SGMS2 – were expressed in the iPSC-HLCs throughout the
differentiation at levels approaching those in PHHs. It has
previously been shown that both SGMS1 and SGMS2 positively
correlate with levels of cellular SM (Li et al., 2007). Our study
supports this because the expression of SGMS1 and SGMS2 correlated
well with several molecular SM species, especially the long-chain
ones (C23 to C26). Furthermore, during the DE differentiation stage, a
sharp increase in total level of SM was observed, whereas PC and
ceramide decreased. SM synthases use ceramide and PC as substrates
to produce SM (Liu et al., 2009), offering an explanation for the
transient decreases of ceramide and PC in the beginning of the hepatic
differentiation. However, this still requires further studies owing to the
Fig. 5. Expression levels of
sphingolipid (SL) metabolism-related
genes during hepatic differentiation
and in primary human hepatocytes
(PHHs). (A) The expression of CERS1,
CERS2, UGCG, SMPD1, SGMS1 and
SGMS2 during hepatic differentiation from
iPSCs at day 0, 5, 10, 15, 20 and 25 as
well as in PHHs. The expression of each
gene was normalised to the endogenous
control gene, GAPDH, and presented
relative to day 0 (iPSCs). Each sample
was run in triplicate and bars represent
means±s.d. of three studied cell lines or
two PHH donors. **P≤0.01; ***P≤0.001.
(B) The expression of CERS2 correlates
positively with Cer d18:1/24:0 (Spearman
r=0.83, P<0.0001), Cer d18:1/23:0
(r=0.78, P<0.001) and Cer d18:1/26:0
(r=0.73, P<0.001). (C) SGMS2 expression
correlates positively with levels of SM
d18:1/24:0 (r=0.85, P<0.0001), SM d18:1/
24:1 (r=0.78, P<0.001) and d18:1/26:1
(r=0.67, P<0.01). Cer, ceramide; CERS,
ceramide synthase; SGMS, sphingomyelin
synthase; SMPD, sphingomyelin
phosphodiesterase; UGCG, UDP-glucose
ceramide glucosyltransferase; SM,
sphingomyelin.
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very complex and dynamic nature of the cellular lipidome, and strong
influence of the culturemedia. Because SM is themost abundant SL in
human cells, its coordinated breakdown is an essential part of
membrane homeostasis. It occurs by the Smase family and results in
the production of ceramide and free phosphocholine. The SMPD1
gene encodes a lysosomal acid Smase, whereas SMPD2, SMPD3 and
SMPD4 are neutral Smases localised to different cellular
compartments (Kim et al., 2008). SMPD2 is located in ER, and
SMPD4 in both ER and Golgi. The expression of SMPD1 increased
during the hepatic differentiation as early as at DE stage, suggesting
that lysosomal degradation of SM might be crucial for differentiation,
maturation or functional structure of the HLCs because ceramide, as
one of the products of SM catabolism, is considered crucial to the
above-mentioned vital cellular processes, as are its derivatives
(Delgado et al., 2006; Gault et al., 2010). Pharmacological
inhibition of SM de novo synthesis decreases not only SM levels
but also ceramide and sphingosine (Liu et al., 2009). This clearly
emphasises that the metabolic conversions among the SLs in the cell
are tightly interconnected. In linewith this, we observed a similar gene
expression pattern between SMPD1, ASAH1 and UGCG during the
entire hepatic differentiation.
GSLs are complex carbohydrate-containing SLs and
characteristic components of plasma membranes, residing
specifically in the membrane microdomains called lipid rafts.
GSL metabolism and composition are altered during the
proliferation and differentiation of various types of cells
(Iwabuchi et al., 2010). LacCer is a precursor in the biosynthesis
of complex GSLs, and known to activate a signal transduction
pathway leading to cell proliferation. In our study, LacCer d18:1/
26:0 as well as three different very-long-chain Glc/GalCer increased
during hepatic maturation. There was also a trend of increased
expression of UGCG (responsible for glycosylation) during the
iPSC-HLC differentiation, correlating with the levels of Glc/
GalCer. This suggests that active UGCG enzyme function is vital
in hepatic maturation because its GSL products are essential players
in cell growth, development and differentiation, and mediate cell
adhesion and modulate signal transduction (Gault et al., 2010).
We detected an overall increase in the FA chain lengths in the
studied SL classes during the differentiation. This might suggest
induction of membrane lateral heterogeneity with more lipid rafts
incorporating SLs with longer chain lengths as the cells differentiate
towards HLCs. The lipid rafts are regarded as small (from 10 to
200 nm) specialised regions of plasma membrane enriched in
cholesterol and SLs with very-long and saturated acyl chains. The
lipid rafts are more ordered and slightly thicker lipid domains than
the surrounding bulk membrane, which contains unsaturated PL
molecules. In line with this, we found significant increase in very-
long and saturated SLs (24:0 and 26:0) (Fig. S5), as well as high
levels of unsaturated PLs provided by medium C from day 7
(Fig. 3C). Signalling and cell-adhesion molecules are localised in
lipid rafts, implicating that these domains may form platforms for
signal transduction and cell adhesion. Complex SLs are needed in
the lipid rafts for example for cell–cell contact and efficient
membrane trafficking (Wassall et al., 2004). However, besides
cholesterol and SLs, the emergence of the raft domains from bulk
membrane also involves unsaturated PLs.
Enrichment of n-3 PUFA in the plasma membrane alters the
lateral organisation of lipids. Polyunsaturated PLs, especially those
with highly unsaturated n-3 PUFAs, are sterically incompatible with
cholesterol and lipids with long saturated acyl chains, and thus the
incorporation of these PUFAs into the membrane PLs forces the raft
lipids out of the bulk membrane, inducing raft formation (Wassall
and Stillwell, 2009). However, supplementing cells in excess with
highly unsaturated FAs, consequently inserted into the membranes,
may disturb raft integrity (Turk and Chapkin, 2013). By regulating
the sizes and properties of the raft versus non-raft domains, the n-3
PUFAs regulate raft-mediated downstream signalling,
transcriptional activation and cytokine secretion (Turk and
Chapkin, 2013). We detected a strong increase in PUFA-
containing PL species during hepatic differentiation. In addition
to driving raft formation, the polyunsaturated PLs affect bulk
membrane properties, such as fluidity, flexibility and permeability
(Rawicz et al., 2008). The changing of these properties affects
membrane vesicle formation and thereby lipid and protein
trafficking, which needs to be efficient as the cells grow,
differentiate and make more membranes (Van Meer et al., 2008).
Very recently, Ghini and co-workers showed that supplementing
culture medium with 22:6n-3 [docosahexaenoic acid (DHA)]
affected both the lipidome and metabolome of HepG2 hepatoma
cells. Owing to the supplement, the total contents of cholesterol,
SFAs andMUFAs decreased, whereas the PUFA and TAG contents
of the cells increased (Ghini et al., 2017). In our study, 22:6n-3 was
present at a very low level in media A, B and C, and present mainly
in medium D, used during the late hepatic maturation. The
precursors of 22:6n-3 (e.g. 18:3n-3), given to the differentiating
cells at an earlier phase, did not immediately give rise to 22:6n-3,
which is likely owing to the required multistep synthetic pathway.
Compared to the synthesis of 20:4n-6 from its precursor 18:2n-6, the
metabolism of 22:6n-3 from 18:3n-3 requires two additional chain
elongations and a desaturation in the ER followed by a peroxisomal
chain-shortening step, the process thus requiring more time and
being less efficient than the synthesis of 20:4n-6 (Tigistu-Sahle
et al., 2017). The HLCs, however, were able to produce some 22:6n-
3 from its precursors, as can be seen from the rising levels of e.g.
22:6-containing PC-P (plasmalogen) during hepatic maturation.
Incorporating 22:6n-3 into PS is crucial to activate protein kinase C
pathways (Aires et al., 2007; Giorgione et al., 1995) and, apparently,
this type of signalling is actively recruited only at late stages of the
differentiation.
PC is the major component of eukaryotic cell membranes and the
major PL component of all plasma lipoprotein classes (Cole et al.,
2012), and is currently the only known PL class to be required for
lipoprotein assembly and secretion (Castro-Gómez et al., 2015). PC
molecules contain a range of FA chains with varying lengths and
double-bond positions (Yamashita et al., 1997). We saw a more
drastic increase (at ∼day 12) of PC species containing FA 20:4, the
precursor of which is an essential FA (18:2n-6), than PCs containing
other PUFAs. This can partly be explained by the concurrent strong
rise of n-6 PUFAs in the medium. When the cells get enough 18:2n-
6 from the medium, they are able to synthesise all the other members
of the n-6 PUFA family (Russo, 2009). However, cellular
remodelling processes prefer producing PC species with 20:4n-6
in the sn-2 position of the molecule: such PC species are the
preferred substrates for cytosolic phospholipase A2 type IV
(PLA2IV), cleaving 20:4n-6 for synthesis of eicosanoids, which
modulate immune responses, cell growth and differentiation
(Astudillo et al., 2012; Fujishima et al., 1999). Apparently, the
capacity of the differentiating cells to produce these lipid mediators
arises along with the appearance of 20:4n-6-containing PC species.
It is especially interesting that, in our cells, APOB expression
peaked and LD were observed at 2 weeks, soon after the maturing
HLCs reached their highest levels of 20:4n-6-containing PC. It was
recently revealed that defects in proteins such as Lpcat3 and
Tm6sf2, needed for efficient incorporation of 20:4n-6 into ER
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membranes, reduce TAG secretion from hepatic cells (Rong et al.,
2015; Ruhanen et al., 2017). Thus, it appears that the 20:4n-6-
containing PC species are crucial for the assembly and excretion of
TAG-containing mature lipoprotein particles, and are likely needed
for the proper function of our cell model, the HLCs. Because these
specific PC species regulate both immune functions and lipid
metabolism of the cells, it is understandable that, when the levels of
these 20:4-containing PCs first increased in the 18:2n-6-rich
medium, they did not peak very high (as happened for many
18:2-containing lipids) but remained at a constant level to the end of
the experiment, independent of the latest switch of the medium. The
levels of 20:4n-6-containing PCs were apparently efficiently
regulated to avoid excessive eicosanoid signalling and to adjust
the rate of lipid secretion from the cells.
Taken together, we show how the lipidome of stem cells is
remodelled in response to supplies available in the cell culture
media and as a result of changing lipid-gene expression as the cells
differentiate and mature towards functional HLCs. The lipidome
and expression of lipid-related genes in HLCs resemble those of
the PHHs, and the HLCs display the expected morphology and
cellular functions of a functional hepatocyte. The observed
elevations in the production of very-long-chain SLs and PUFA-
containing PLs during hepatic maturation clearly show that cells
efficiently take up FAs from the media, incorporate them and
modify simple lipids into more complex ones, which in turn can
change the membrane architecture, causing the alterations in
cellular functions.
Conclusions
Here, we show an efficient differentiation of iPSCs to HLCs and
demonstrate their functionality determined by their cellular
lipidomic fingerprint in conjunction with biochemical and
functional measurements and lipid-metabolism-focused gene
expression. To our knowledge, this is the first time a lipidomic
profile has been acquired of stem cells during the course of their
maturation into functional HLCs. We anticipate that the described
approach will open up new avenues in lipid-focused stem-cell
biology and medicine as it provides detailed maps of the underlying
lipid content and metabolism of a cell at a given time point, taking
into account the cell culture environment and FA components
available in the culture media. This provides a novel tool in utilising
the lipidome to follow cell differentiation and maturation and how
this is affected under different conditions or stimuli. Thus, we
expect that the stem-cell lipidomic fingerprinting through HLC
differentiation will facilitate the production of target cells that more
closely resemble the primary human hepatocytes, helping to
improve our understanding of many hepatocyte-related diseases
and their treatments.
MATERIALS AND METHODS
iPSC culture
iPSC lines were maintained at 37°C in 5% CO2 on mitotically inactivated
mouse embryonic fibroblasts (MEFs; Applied StemCell, cat. no. ASF-
1223). Cells were treated with KnockOut Dulbecco’s modified Eagle
medium (KO-DMEM) supplemented with 20% KnockOut Serum
Replacement (Ko-SR), 2 mM GlutaMAX, 0.1 mM 2-mercaptoethanol (2-
ME) (all from Gibco), 1% nonessential amino acids (NEAA) and 50 U/ml
penicillin/streptomycin (both from LONZA). Medium was supplemented
with 4 ng/ml human basic fibroblast growth factor (bFGF; R&D System).
To generate HLCs, iPSCs were adapted to feeder-free condition on pre-
coated plates with Geltrex (Gibco®, 1:100 dilution) in mTeSR medium
(=medium A) before hepatic differentiation. Cell lines were checked for
mycoplasma contamination.
iPSC reprogramming
Three iPSC lines (UTA.10100.EURCAs, UTA.11104.EURCAs and
UTA.11304.EURCCs) were used in this study. The lines were derived
directly from the fibroblast of three individual patients. The study was
approved by the Ethical Committee of Pirkanmaa Hospital District
(R12123) and written consent was obtained from all fibroblast donors.
The collected fibroblasts were induced to pluripotency using the Sendai
reprogramming kit (OCT4, SOX2, KLF4, C-MYC; CytoTune; Life
Technologies) based on the protocol described by Takahashi et al. (2007).
Cell lines were induced according to the manufacturer’s instructions and
cultured on MEF feeders until characterisation.
iPSC characterisation
All the iPSC lines were characterised in detail as described before (Manzini
et al., 2015). In short, we used PCR to study the expression of endogenous
pluripotency genes (NANOG, REX1, OCT3/4, SOX2 and c-MYC) and the
absence of virally imported exogenes (OCT4, SOX2, c-MYC and KLF4).
Immunocytochemistry was performed to study the protein expression of
pluripotency markers (Nanog, OCT-3/4, SOX2, SSEA-4, TRA 1-60 and
TRA 1-81) (Table S1). The normal karyotype of the iPSC lines was
confirmed by performing genome-wide screening for gross chromosomal
abnormalities with KaryoLite BoBs (product number 4501–0010, Perkin
Elmer) in the Finnish Microarray and Sequencing Centre, as described
elsewhere (Lund et al., 2012).
The pluripotency of the iPSCs was verified in vitro by the formation of
embryoid bodies (EBs) from which RNA was extracted and reverse
transcription performed as described previously (Manzini et al., 2015).
The expression of marker genes characteristic of endoderm (SOX17 or
AFP), mesoderm (KDR or ACTC1) or ectoderm (nestin or musashi) were
studied from EBs by PCR and GAPDH was used as an endogenous control.
The primer sequences for pluripotency genes and virally imported exogenes
as well as for marker genes of the three germ layers are presented in
Table S2.
Hepatic differentiation
Hepatic differentiation was performed according to the protocol developed
by Hay et al. (2008). After the colonies became 60-70% confluent,
differentiation was initiated by culturing the cells in RPMI1640+GlutaMAX
medium (Gibco) supplemented with 100 ng/ml Activin A (R&D Systems),
75 ng/ml Wnt3, 1 mM sodium butyrate (NaB) on the first day and 0.5 mM
from day 2, and 2% B27 (Gibco) (=medium B) for 5-6 days to DE stage.
Hepatic differentiation was initiated by switching the medium to KO-
DMEM+20% Knockout Serum Replacement, 1 mM GlutaMAX, 1%
NEAA, 0.1% 2-ME and 1% dimethyl sulfoxide (DMSO) (=medium C)
for 7 days. From this point cells were cultured in Leibovitz’s L-15 medium
(Invitrogen), supplemented with 8.3% fetal bovine serum (FBS) (Biosera),
8.3% tryptose phosphate broth (Sigma-Aldrich), 10 µM hydrocortisone
21-hemisuccinate, 1 mM insulin (both from Sigma-Aldrich), 2 M
GlutaMAX, 25 ng/ml hepatocyte growth factor (HGF) and 20 ng/ml
oncostatin M (R&D Systems) (=medium D) (Fig. 1A).
Hepatic characterisation
Flow cytometry
DE cells were detached at day 5 by a 7- to 8-min incubation with Gentle Cell
Dissociation Reagent (StemCell Technologies) at 37°C and then suspended
in 3% FBS before being stained by CXCR4 conjugated antibody (R&D
Systems) for 15 min at room temperature (RT). The percentage of CXCR4-
positive cells were assessed using a BD Accuri C6 cytometer.
Real-time quantitative PCR (RT-qPCR) analyses
RNA samples were collected at days 0, 5, 10, 15, 20 and 25 using the
RNeasy kit (Qiagen, cat. no. 74106). cDNAs were generated using the High
Capacity cDNA Reverse Transcription kit (Applied Biosystems, USA)
according to the manufacturer’s instructions in the presence of RNase
inhibitor. The PCR reaction was performed by using Power SYBR Green
PCR Master Mix (Life Technologies, cat. no. 1408470) and the cDNAwas
multiplied using the Applied Biosystems 7300 Real-time Sequence
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Detection system. CT values were determined using 7300 SDS software
(Applied Biosystems) and relative quantification was calculated by the
2−ΔΔCT method (Livak and Schmittgen, 2001). The primer sequences are
presented in Table S3.
The expression of 18 genes involved in lipoprotein formation or SL
metabolism was studied by RT-qPCR with the Biomark HD system
(Fluidigm Corp., San Francisco, USA) and using TaqMan assays. cDNA
was prepared and pre-amplified according to the manufacturer’s
instructions, as were the RT-qPCR reactions. TaqMan assays (Life
Technologies) used in the RT-qPCR are presented in Table S4. The levels
of mRNA expression were normalised to the endogenous control gene,
GAPDH, and expressed as relative expression compared to the
undifferentiated iPSCs (at day 0). Each sample was run in triplicate.
Immunocytochemistry
Cultured cells were fixed in 4% paraformaldehyde (PFA) for 20 min at RT.
Permeabilization and blocking was performed at the same time by 10%
normal donkey serum (NDS), 0.1% Triton-X 100 and 1% bovine serum
albumin (BSA) for 45 min. Cells were incubated overnight with primary
antibodies (Table S1) in the above solution with reduced NDS to 1%.
Antigens were visualised using Alexa Fluor 488- and 568-conjugated
secondary antibodies (Table S1). Finally, the cells were mounted with
Vectashield (Vector Laboratories Inc., Burlingame, CA, USA) containing
40,6-diamidino-2-phenylindole (DAPI) for the nuclei staining and imaged
with an Olympus IX51 phase-contrast microscope equipped with
fluorescence optics and an Olympus DP30BW camera (Olympus
Corporation, Hamburg, Germany).
Functionality of the differentiated iPSC-HLCs
The ability of the iPSC-HLCs to both uptake LDL and secrete albumin was
studied using the LDL Uptake Assay kit (Cayman Chemicals, USA) and
Human Albumin ELISA Quantitation set (Bethyl Laboratories, USA),
respectively, according to the manufacturers’ instructions. Secreted albumin
was measured from 24-h conditioned medium and normalised to the cell
number.
Lipidomic profiling of cells and FA analyses of cell culture media
Lipid sample preparation and extraction
Lipids [CEs, SLs, glycerophospholipids (GPL) and polar glycerolipids] were
extracted at days 0, 6, 12, 16, 20, 24 and 28 of differentiation from PBS-
resuspended cells by a modified Folch lipid extraction, using chloroform
[high-performance liquid chromatography (HPLC) grade], methanol and
acetic acid [both liquid-chromatography–mass-spectrometry (LC-MS) grade]
for liquid−liquid extraction (Ståhlman et al., 2009), which was performed on
96-well plates employing a Hamilton Microlab Star system (Hamilton
Robotics AB, Kista, Sweden). All solvents were purchased from Sigma-
Aldrich. Samples were spiked with known amounts of lipid-class-specific
non-endogenous synthetic internal standards. After lipid extraction, samples
were reconstituted in chloroform:methanol (1:2, v/v) and synthetic external
standards were post-extract spiked to the extracts (Heiskanen et al., 2013).
Quality control samples (QCs) were prepared along with the actual samples
for all lipidomic analyses to monitor the extraction and MS performance. In
addition, calibration lines were prepared to determine the linear dynamic
range of the MS analyses. QCs and calibration lines were prepared in fresh
frozen plasma (FFP) samples (Veripalvelu, Finland).
Mass spectrometric analyses and data processing
In shotgun lipidomics, lipid extracts were analysed on a hybrid triple
quadrupole/linear ion trap mass spectrometer (QTRAP 5500) equipped
with a robotic nanoflow ion source (NanoMate, Advion Biosciences Inc.,
Ithaca, NJ, USA) as described (Heiskanen et al., 2013). Molecular lipids
were analysed in both positive and negative ion modes using either
multiple precursor ion or neutral loss scans (Ekroos et al., 2002, 2003).
The molecular species of lipids were identified and quantified in absolute
[CE; PC; phosphatidylethanolamine (PE); phosphatidylserine (PS);
lysophosphatidylcholine (LPC); lysophosphatidylethanoamine (LPE);
DAG; SM] or semi-absolute [PI; alkyl-linked phosphatidylcholine (PC-
O); alkenyl-linked phosphatidylcholine (PC-P); alkyl-linked PE (PE-O);
alkenyl-linked PE (PE-P)] amounts (Ejsing et al., 2006) by normalising
to their respective synthetic internal standard and the sample amount.
SLs were analysed as described before (Merrill et al., 2005), using an
Acquity BEH C18, 2.1×50 mm column with a particle size of 1.7 µm
(Waters, Milford, MA, USA). A 25 min gradient using 10 mM ammonium
acetate in water with 0.1% formic acid (mobile phase A) and 10 mM
ammonium acetate in acetonitrile:2-propanol (4:3, v/v) containing 0.1%
formic acid (mobile phase B). SLs were analysed on a hybrid triple
quadrupole/linear ion trap mass spectrometer (4000/5500 QTRAP)
equipped with an ultra-high-pressure liquid chromatography (UHPLC)
system (CTC HTC PAL autosampler and Rheos Allegro pump or
Shimadzu Nexera X2) using a multiple reaction monitoring (MRM)-
based method in negative ion mode.
Molecular lipids were normalised to the total protein concentration in the
cell samples. Total protein concentrations were determined using the Micro
BCA Protein Assay kit (Thermo Scientific Pierce Protein Research
Products) according to the manufacturer’s instructions. Data processing
was performed by MultiQuant, LipidProfiler/LipidView (AB Sciex)
softwares and SAS.
FA analysis
FA composition and concentrations in the cell culture media (mediumA,B, C
and D, see above for details) used at iPSC stage and at different stages of
hepatocyte differentiation were analysed by gas chromatography. First, the
lipid residues of nitrogen-dried media were subjected to transmethylation in
1% methanolic H2SO4 at a temperature of 96°C and under nitrogen
atmosphere for 120 min, according to the recommendations of Christie
(1993). The FA methyl esters (FAMEs) formed were recovered with hexane
and their quantitative analysis was performed using a Shimadzu GC-2010
Plus gas chromatograph with ﬂame-ionization detector (GC-FID). The
FAME structures were identiﬁed by Shimadzu GCMSQP2010 Ultra with
mass selective detector (GC-MSD). Both GCequipments were equippedwith
ZB-wax capillary columns (30 m, 0.25 mm ID, 0.25 μm film, Phenomenex,
USA). When calculating the composition, the FID responses were corrected
according to the theoretical response factors (Ackman, 2007) and, when
calculating the concentrations in medium, the FAME 13:0 (not present in the
samples) was used as an internal standard. In the Results, the FAs were
marked by using the abbreviations: [carbon number]:[number of double
bonds] n-[position of the first double bond calculated from the methyl end]
(e.g. 22:6n-3).
Statistical analyses
Gene expression data
GraphPad Prism version 5.02 software was used for the data analysis. The
standard deviation (s.d.) was calculated from the average of three
independent samples. Statistical analyses comparing gene expression
levels in more than two groups was performed with one-way ANOVA
and P<0.05 was considered statistically significant.
Lipidomic data
Statistical analyses for lipidomic data was performed with R (version x64
3.2.1). Zero values in the data were imputed with a value corresponding to
half of the minimum value of the corresponding lipid across all the samples.
PCA was performed for the log2-transformed data applying centering and
scaling. Heat maps were generated with gplots package by calculating the
mean log2 fold change to samples at day 0 or 12.
Correlation analyses
Correlation analyses (Spearman) were performed to study whether the
expression of SL metabolism genes pairs with relevant lipid parameters and
how strong the potential correlation is.
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Holmgren, G., Sjögren, A.-K., Barragan, I., Sabirsh, A., Sartipy, P., Synnergren,
J., Björquist, P., Ingelman-Sundberg, M., Andersson, T. B. and Edsbagge, J.
(2014). Long-term chronic toxicity testing using human pluripotent stem cell-
derived hepatocytes. Drug Metab. Dispos. 42, 1401-1406.
Hornemann, T. and Worgall, T. S. (2013). Sphingolipids and atherosclerosis.
Atherosclerosis 226, 16-28.
Hu, C. and Li, L. (2015). In vitro culture of isolated primary hepatocytes and stem
cell-derived hepatocyte-like cells for liver regeneration. Protein Cell 6, 562-574.
Iwabuchi, K., Nakayama, H., Iwahara, C. and Takamori, K. (2010). Significance of
glycosphingolipid fatty acid chain length on membrane microdomain-mediated
signal transduction. FEBS Lett. 584, 1642-1652.
Kim, W. J., Okimoto, R. A., Purton, L. E., Goodwin, M., Haserlat, S. M., Dayyani,
F., Sweetser, D. A., Mcclatchey, A. I., Bernard, O. A., Look, A. T. et al. (2008).
Mutations in the neutral sphingomyelinase gene Smpd3 implicate the ceramide
pathway in human leukemias. Blood 111, 4716-4722.
Laviad, E. L., Albee, L., Pankova-Kholmyansky, I., Epstein, S., Park, H., Merrill,
A. H. and Futerman, A. H. (2008). Characterization of ceramide synthase 2:
Tissue distribution, substrate specificity, and inhibition by sphingosine 1-
phosphate. J. Biol. Chem. 283, 5677-5684.
Leung, A., Nah, S. K., Reid,W., Ebata, A., Koch, C.M., Monti, S., Genereux, J. C.,
Wiseman, R. L., Wolozin, B., Connors, L. H. et al. (2013). Induced pluripotent
stem cell modeling of multisystemic, hereditary transthyretin amyloidosis. Stem
Cell Rep. 1, 451-463.
Levy, M. and Futerman, A. H. (2010). Mammalian ceramide synthases. IUBMB Life
62, 347-356.
Li, Z., Hailemariam, T. K., Zhou, H., Li, Y., Duckworth, D. C., Peake, D. A., Zhang,
Y., Kuo, M.-S., Cao, G. and Jiang, X.-C. (2007). Inhibition of sphingomyelin
synthase (SMS) affects intracellular sphingomyelin accumulation and plasma
membrane lipid organization. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1771,
1186-1194.
Liu, J., Zhang, H., Li, Z., Hailemariam, T. K., Chakraborty, M., Jiang, K., Qiu, D.,
Bui, H. H., Peake, D. A., Kuo, M.-S. et al. (2009). Sphingomyelin synthase 2 is
one of the determinants for plasma and liver sphingomyelin levels in mice.
Arterioscler. Thromb. Vasc. Biol. 29, 850-856.
Livak, K. J. and Schmittgen, T. D. (2001). Analysis of relative gene expression data
using real-time quantitative PCR and the 2−ΔΔCT method.Methods 25, 402-408.
Llorente, A., Skotland, T., Sylvänne, T., Kauhanen, D., Róg, T., Orłowski, A.,
Vattulainen, I., Ekroos, K. and Sandvig, K. (2013). Molecular lipidomics of
exosomes released by PC-3 prostate cancer cells. Biochim. Biophys. Acta Mol.
Cell Biol. Lipids 1831, 1302-1309.
Lucendo-Villarin, B., Filis, P., Swortwood, M. J., Huestis, M. A., Meseguer-
Ripolles, J., Cameron, K., Iredale, J. P., O’Shaughnesy, P. J., Fowler, P. A.
and Hay, D. C. (2017). Modelling foetal exposure to maternal smoking using
hepatoblasts from pluripotent stem cells. Arch. Toxicol. 91, 1-11.
Lund, R. J., Nikula, T., Rahkonen, N., Närvä, E., Baker, D., Harrison, N.,
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